Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 654 vs Ustekinumab in Moderate to Severe Plaque Psoriasis
NCT04607980Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of ustekinumab biosimilar ABP 654 in plaque psoriasis, sponsored by Amgen. Started Nov 2020; status: completed.
02
Drugs
ustekinumab biosimilar ABP 654
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04607980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607980.